GSK Bio
NEWS
Eli Lilly is jumping into the RIPK1 chase, paying $125 million up front to partner with Rigel Pharmaceuticals to co-develop its lead RIPK1 inhibitor program across all indications.
In 2020, Vir and GlaxoSmithKline partnered to develop strategies against COVID-19. The two companies have expanded that collaboration to include work into new treatments for influenza and other respiratory viruses.
Biotech investor Neil Woodford is poised for a comeback after a fall from grace two years ago.
Under the terms of the deal, Sandoz is paying GSK $350 million at closing and additional milestones up to $150 million.
There are some big surprises among the list of major players in the vaccine space who either dropped their programs or have been significantly delayed.
Billionaire Sir Richard Branson believes in healthcare. This week he put more of his money where his mouth is by using his SPAC to take consumer DNA testing company 23andMe public in a massive deal.
It was a busy week for clinical trial updates. Here’s a look.
Treatments for HIV are poised for another breakthrough. Researchers at Washington University in St. Louis (WUSTL) have discovered a way to eradicate dormant HIV virus within the cells, before it becomes active.
The collaboration is valued at €150 million (approximately $180 million). The two companies already have a history of working together.
JOBS
IN THE PRESS